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gans in vertebrates. In addition to playing a part in the circadian cycle of the body, melatonin
is known to have antioxidant, antiinflammatory, and antioncotic effects on human tissues. Oral
cavity is affected by a number of conditions such as periodontitis, mucositis, cancers, and
cytotoxicity from various drugs or biomaterials. Research has suggested that melatonin is
effective in treating the aforementioned pathologies. Furthermore, melatonin has been
observed to enhance osseointegration and bone regeneration. The aim of this review is to crit-
ically analyze and summarize the research focusing on the potential of melatonin in the field of
oral medicine. Topical administration of melatonin has a positive effect on periodontal health
and osseointegration. Furthermore, melatonin is particularly effective in improving the peri-
odontal parameters of diabetic patients with periodontitis. Melatonin exerts a regenerative ef-
fect on periodontal bone and may be incorporated into of periodontal scaffolds. The cytotoxic
effect of various drugs and dental materials may be countered by the antioxidant properties of
melatonin. Topical administration of melatonin promotes the healing of tooth extraction
sockets and may also impede the progression of oral cancer. Although, there are a number
of current and potential applications of melatonin, further long term clinical and animaleclare no conflicts of interest.
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methoxy tryptamine).studies are needed to assess its efficacy. Moreover, the role of melatonin supplements in the
management of periodontitis should also be assessed.
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Melatonin (N-acetyl-5-methoxy tryptamine) is a substance
secreted by multiple organs including the pineal gland,
retina, bone marrow, the gastro-intestinal track, and the
immune system. Its main function is the regulation of the
circadian rhythm (dayenight cycles) [1]. It plays an anti-
inflammatory, antioncotic, and immunomodulatory role by
scavenging free-radicals and via interactions with cell
membrane and intracellular proteins [2]. The chemical
structure of melatonin is shown in Figure 1.
Melatonin is capable of entering the oral cavity by
diffusing into the saliva from blood. As the majority of the
melatonin remains bound to serum albumin, the amount
of melatonin in saliva is approximately one third of that
present in the blood [3]. Melatonin mainly exerts antiox-
idant effects by interacting with melatonin receptor 1
(MT1) and melatonin receptor 2 (MT2) receptors on cells
[4,5]. Perhaps, a potent antiinflammatory property of
melatonin is linked to its ability to act as a scavenger of
exogenous and endogenous reactive oxygen species (ROS)
and reactive nitrogen species (RNS) [6]. In addition, both
ROS and RNS have been associated with DNA mutations
leading to carcinogenesis [7]. The existence of MT1 re-
ceptors on healthy and cancerous oral mucosal cells is
suggestive that melatonin may act as an antiinflammatory
or antioncotic agent in the oral cavity [8]; for example, its
antiinflammatory effects have been reported on human
gingival fibroblasts [9]. Furthermore, intraperitoneal
melatonin has been reported to reduce periodontitis in
diabetic rats [10]. Similarly, topical application of mela-
tonin in diabetic patients has diminished the progression
of periodontal bone loss as evident by the down-
regulation of proinflammatory factors [11e13]. Hence, it
has been suggested that melatonin may be used in the
management of periodontitis and antioncotic agents for
oral cancer cells [8,14,15]. The aim of this review is to
critically analyze and summarize the research focusing on
the potential of melatonin in the fields of oral medicine
and periodontology.of melatonin (N-acetyl-5-Melatonin for the treatment of periodontitis
Periodontitis results in progressive destruction of tooth
supporting tissues (cementum, periodontal ligament, and
alveolar bone) and subsequently loss of teeth. In spite of
various surgical and nonsurgical therapeutic options, the
global prevalence of periodontitis is still remarkably high
(40e90%) [16]. In addition to in vitro studies [9], animal
studies and clinical trials have documented the therapeutic
effects of melatonin on periodontitis (Table 1).
Local and systemic administration ofmelatonin in ratswith
lipopolysaccharide-induced periodontitis reduced the level of
enzymes (such as serum aspartate aminotransferase, alanine
transaminase, and blood urea nitrogen) significantly
compared with rats in the control group [17,18]. Similarly,
locally administered melatonin significantly reduced bone
resorption compared with rats receiving no treatment. These
studies suggested that topical administrationofmelatonin can
be used as an adjunct to conventional treatment protocols
such as scaling, root planing, and surgical debridement to
improve the outcomes of periodontal therapy.
As diabetes mellitus has a two-way relationship with
periodontal diseases [19], melatonin has been used for
therpeutic applications for cases of diabetes-induced per-
diontitis. It has been reported that administration of
melatonin reduced osteoclast activity and alveolar bone
loss in the diabetic rats with periodontitis melatonin [20].
In addition, diminished oxidative stress index and reduced
alveolar bone loss have been observed in similar diabetic
animal models [10]. The effects of melatonin on diabetic
patients appear twofold: (1) the inherent antiinflammatory
and antioxidant properties of melatonin reduce the
magnitude of inflammation in the periodontal tissues [2];
and (2) melatonin scavenges the ROS produced due to
diabetes and, therefore, reduces the inflammatory effects
of diabetes on the periodontium [21].
Melatonin not only down-regulates the expression of
proinflammatory factors such as C-reactive protein,
interleukin-6, and tumor necrosis factor-alpha [11], but it
also down-regulates receptor activators of nuclear factor
kappa-B ligand/osteoprotegerin ratios to reduce peri-
odontal inflammation [11e13]. In addition to up-regulation
of salivary acid phosphatase, alkaline phosphatase, osteo-
pontin, and osteocalcin, it results in significant improve-
ments in gingival index and pocket depth. These facts are
indicative of enhanced osteoblast differentiation and bone
formation following topical administration of melatonin
[12]. However, further well-designed studies with longer
follow-up periods are needed to ascertain the long-term
efficacy of melatonin in treating periodontitis in the clin-
ical settings.
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Melatonin in oral medicine and periodontology 393Melatonin and osseointegration of dental implants
Dental implants require surface modifications in order to
increase their bioactivity prior to their placement in peri-
odontal bone [22,23]. However, there are several draw-
backs of modified implants such as delamination of the
bioactive coating, ion leakage, and particle residues [23].
Melatonin has the potential to act as a viable alternative to
unstable implant coatings. Administration of powdered
melatonin to implant sites resulted in significantly higher
interthread bone formation and bone mineralization in
experimental dogs compared with control implant sites
[24]. Melatonin augments the osteogenic effects of porcine
bone grafts on calcium-coated titanium dental implants
placed in experimental dogs [25]. Moreover, combination
with growth hormone seems to augment the effects of
melatonin on implant sites in vivo [26]. Intraperitoneal in-
jections of melatonin combined with fibroblast growth
factor-2 (FGF-2) around titanium and zirconia implants
have been observed to promote a greater boneeimplant
contact [27,28]. Results obtained in a 3-month clinical trial
suggest that melatonin may prove to be clinically effective
to enhance the osseointegration of dental implants [29].
Nevertheless, more long-term animal and human studies
are indeed required to further explore the osteoconductive
effect of melatonin on implants.Melatonin for countering the cytotoxicity of drugs
and dental materials
A number of drugs are known to affect the periodontium.
Proksch et al. [30], reported that melatonin reduced the
levels of reactive oxidative species and cytotoxic effects of
commonly used oral antiseptic medicaments (e.g., chlor-
hexidine). Melatonin also plays a protective role against the
necrotic effects of bisphosphonates on periodontal cells
[31]. Therefore, topical application of melatonin prior to
dental surgery may prevent bisphosphonate-related osteo-
necrosis of the jaws. Methacrylate compounds present in
commonly used dental polymers are known to have cyto-
toxic effects [32]. Due to antioxidant properties, melatonin
has been observed to protect dental pulp cells against DNA
damage due to methacrylate [33]. Therefore, melatonin, in
the form of sublingual tablets, gels, or mouth rinses has the
potential to inhibit the genotoxic effects of methacrylate-
based dental materials.Application of melatonin in postextraction tooth
sockets
Tooth extraction is a traumatic surgical procedure. Pro-
duction of ROS and RNS contributes to manifestation of
inflammation and/or infection at the site of extraction
[6,34]. Indeed, placement of melatonin in the extraction
sockets of dogs normalizes the levels of lipid peroxides,
nitrates, and nitrites raised in reaction to tooth extraction
[35]. By contrast, a clinical study conducted on 10 patients
failed to replicate the effects of melatonin observed in
animal studies [36]. Therefore, efficacy of applying topical
melatonin on postextraction sockets is debatable and more
Figure 2. Therapeutic potential of melatonin in oral medi-
cine and periodontology.
394 S. Najeeb et al.research is required to assess its potential for clinical
applications.
Effect of melatonin on bone regeneration
As discussed earlier, melatonin is known to stimulate the
proliferation of osteoblasts and promote bone formation
[37]. Additionally, the immunomodulatory, antioxidant,
and antiinflammatory effects may further add to the
osteoconductive effects of melatonin [38,39]. Bioactive
scaffolds and bone grafting materials are used to induce
regeneration of bone which has been lost due to peri-
odontal disease or tooth loss [40]. It has been observed that
calcium aluminate scaffolds, containing melatonin and
platelet-rich plasma have a proliferative effect on human
osteoblasts [41]. Melatonin-based scaffold hold a promising
outcome in guided tissue regeneration applications in the
future.
Effect of melatonin on oral cancer
As ROS are involved in the manifestation of precancerous
lesions such as leukoplakia and lichen planus [42,43],
melatonin plays a preventative or therapeutic role against
oral cancer due to its antioxidant properties. Additionally,
melatonin prevents damage to healthy tissues due to
radiotherapy, which is routinely employed to treat oral
cancers [44]. A recent in vitro study suggests that mela-
tonin may impede metastasis of oral cancer by inhibiting
metalloproteinase-9 activation [45]. Therefore, oral rinses,
gels, and toothpastes containing melatonin may be bene-
ficial for impeding and preventing oral cancer.
Melatonin as an antimicrobial agent
Melatonin possesses antimicrobial properties against a va-
riety of bacteria and viruses [46,47]. However, to the au-
thors’ best knowledge, no studies have been conducted
testing the effects of melatonin against cariogenic bacteria
such as Staphylococcus mutans and Lactobacillus. Never-
theless, in 1976, a study by Mechin and Toury [48] reported
significantly reduced caries in rats receiving intraperitoneal
injections of melatonin compared with those receiving no
melatonin injections. The direct antimicrobial action of
melatonin, synergistically supported by its immunomodu-
latory and antioxidant properties may prove to be a potent
weapon against numerous oral infections.
Limitations of melatonin in oral medicine and
periodontology
In spite of various studies suggesting a potential of mela-
tonin in various fields of dentistry, there are some limi-
tations that should be overcome. Although the positive
impact of melatonin on general health has been suggested
[49], no studies have attempted to analyze the impact of
increased intake of melatonin-rich foods such as grapes,
bananas, herbs, rice, and cereals on the periodontal
health or periodontal treatment. Food and Drug Associa-
tion has approved melatonin as a supplement for thetreatment of insomnia and sleep-disorders [50]. However,
to date, no studies have evaluated the impact of dietary
melatonin supplements on periodontal parameters.
Studies should be conducted to observe the effect of using
systemic melatonin alongside conventional nonsurgical
and surgical therapy to assess its feasibility as a long-term
therapeutic agent for the management of periodontitis.
Well-designed, multicenter studies should be conducted
before melatonin may be accepted in routine dental
practice. Additionally, there is a lack of research focusing
on the effect of melatonin on the growth of periodontal
and peri-implant microflora. Therefore, generally
speaking, more studies are needed to construe a safe and
effective dose of melatonin in oral medicine.
In conclusion, a number of positive effects of melatonin
on the periodontium and its potential therapeutic roles
have been documented in literature (see Figure 2). Mela-
tonin shows promise in the management of diabetes-
associated periodontitis, periodontal regeneration, oral
implantology, and preventative dentistry. However, more
clinical as well as animal studies are required to ascertain
the use of melatonin in the clinical setting.References
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